MEMORANDUM

TO: North Carolina Immunization Program (NCIP) Participants

FROM: Wendy Holmes, RN, Acting Head Immunization Branch

SUBJECT: Availability of Combination Hib and Meningococcal Vaccine, Hib-MenCY-TT, MenHibrix®

The purpose of this memo is to announce the availability of Hib-MenCY-TT vaccine. The vaccine is a combination vaccine that protects against meningococcal groups C and Y and Haemophilus influenzae type B (Hib). Currently there is a single Hib-MenCY-TT product, manufactured by GlaxoSmithKline Biologicals, known as MenHibrix®. Not every provider will need to keep Hib-MenCY-TT in inventory, as it is only recommended for severely immunocompromised infants 6 weeks through 23 months of age.

When the Advisory Committee on Immunization Practices (ACIP) voted to add Hib-MenCY-TT to the Vaccines for Children (VFC) Program, they stated their intention was to focus the routine use of this combination vaccine among infants at increased risk for meningococcal disease which include:
- Infants with persistent complement pathway deficiencies, anatomic or functional asplenia, or sickle cell disease; and,
- Infants who live in or will travel to communities with serogroups C and Y meningococcal disease outbreaks.

More details about children at increased risk for meningococcal disease can be found at: http://bit.ly/MenHibrixMMWR.

MenHibrix® is only available for high-risk, VFC eligible patients. Providers may place orders in single-dose increments through the North Carolina Immunization Registry (NCIR) or by faxing a Vaccine Requisition Inventory Form to 1-800-544-3058.

Questions about the vaccine should be addressed to your regional immunization consultant or the Immunization Helpdesk at 1-877-873-6247.